> Details

Chevallier, Patrice; Leguay, Thibaut; Delord, Marc; Salek, Cyril; Kim, Rathana; Huguet, Françoise; Hicheri, Yosr; Wartiovaara-Kautto, Ulla; Raffoux, Emmanuel; Cluzeau, Thomas; Balsat, Marie; Roth-Guepin, Gabrielle; Tavernier, Emmanuelle; Lepretre, Stephane; Bilger, Karin; Bergugnat, Hugo; Berceanu, Ana; Alexis, Magda; Doubek, Michael; Brissot, Eolia; Hunault-Berger, Mathilde; Lebon, Delphine; Turlure, Pascal; Chantepie, Sylvain; [...]

Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22 + Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia
  • Contributor: Chevallier, Patrice; Leguay, Thibaut; Delord, Marc; Salek, Cyril; Kim, Rathana; Huguet, Françoise; Hicheri, Yosr; Wartiovaara-Kautto, Ulla; Raffoux, Emmanuel; Cluzeau, Thomas; Balsat, Marie; Roth-Guepin, Gabrielle; Tavernier, Emmanuelle; Lepretre, Stephane; Bilger, Karin; Bergugnat, Hugo; Berceanu, Ana; Alexis, Magda; Doubek, Michael; Brissot, Eolia; Hunault-Berger, Mathilde; Lebon, Delphine; Turlure, Pascal; Chantepie, Sylvain; [...]
  • Published: American Society of Clinical Oncology (ASCO), 2024
  • Published in: Journal of Clinical Oncology (2024)
  • Language: English
  • DOI: 10.1200/jco.24.00490
  • ISSN: 1527-7755; 0732-183X
  • Origination:
  • Footnote:
  • Description: PURPOSE The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL. PATIENTS AND METHODS EWALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870 ). Patients age 55 years and older with newly diagnosed CD22 + Philadelphia chromosome–negative (Ph–) B-cell precursor (BCP) ALL were eligible. After a prephase, a first induction consisting of vincristine, dexamethasone, and three injections of InO (0.8 mg/m 2 day 1, 0.5 mg/m 2 day 8/day 15) was followed by a second induction combining cyclophosphamide, dexamethasone, and two injections of InO (0.5 mg/m 2 day 1/day 8). Responders received up to six cycles of chemotherapy consolidation and 18-month chemotherapy maintenance. Allotransplant was allowed after three consolidations. The primary end point was 1-year overall survival (OS). RESULTS Between December 2017 and March 2022, 131 patients (median age 68 years) were included. Three patients died during induction 1 (n = 130), two from multiple organ failure and one from hemorrhage, and none during induction 2 (n = 120). After induction 2, 90% of the patients achieved complete remission (CR) or CR with incomplete platelet recovery (CRp) and 80% had measurable residual disease (MRD2) <10 −4 . Among responders (n = 119), 47 relapsed and 14 died in CR/CRp. One-year OS, relapse-free survival (RFS), and cumulative incidence of relapse (CIR) rates were 73.2%, 66%, and 25%, respectively. High-risk cytogenetics and lower CD22 expression (<70%) were associated with worse OS, while both high-risk cytogenetics and MRD2 ≥10 −4 were associated with lower RFS and higher CIR. The 10 allotransplanted patients had very favorable outcomes (90% 2-year OS/RFS and no relapse). Only one nonfatal sinusoidal obstructive syndrome was documented during the study. CONCLUSION Our results support InO's use in first-line regimens for older patients with CD22 + Ph– BCP-ALL.